Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Key facts

Sponsor

Goethe University

Principal Investigator

Nicola Goekbuget, MD

Department of Medicine, Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany

Intervention

Isatuximab(drug)

Enrollment

40 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2028

Study locations (14)

• University Hospital Augsburg, II. Medizinischen Klinik, Hämatologie, internistische Onkologie und Hämostaseologie, Augsburg, Germany
• Charité Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumorimmunologyt Hämatologie, Berlin, Germany
• Klinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany
• University Hospital Düsseldorf, Department of Hematology, Oncology and Clinical Immunology, Düsseldorf, Germany
• University Hospital Erlangen AöR, Department of Medicine 5, Erlangen, Germany
• Goethe University Hospital Frankfurt, Department of Medicine, Hematology and Oncology, Frankfurt am Main, Germany
• University Hospital Hamburg-Eppendorf, Department of Medicine II, Hamburg, Germany
• University Hospital Heidelberg, Department V, Hematology, Oncology and Rheumatology, Heidelberg, Germany
• University Hospital Schleswig-Holstein, Campus Kiel, Medical Department II, Kiel, Germany
• University Hospital Leipzig; Klinik für Hämatologie, Zelltherapie, Hämostaseologie und Infektiologie, Bereich Hämatologie und Zelltherapie, Leipzig, Germany
• University Hospital München-Großhadern, Medizinische Klinik und Poliklinik III, München, Germany
• University Hospital Münster, Medizinische Klinik A / KMT-Zentrum, Münster, Germany
• Klinikum Oldenburg AöR, Universitätsklinik für Innere Medizin - Onkologie und Hämatologie, Oldenburg, Germany
• Robert-Bosch-Krankenhaus; Abteilung für Hämatologie, Onkologie und Palliativmedizin, Stuttgart, Germany

Collaborators

Sanofi

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Precursor T-cell acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07070323
  A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
  Beijing GoBroad Hospital

See all trials for Precursor T-cell acute lymphoblastic leukemia →